论文部分内容阅读
目的探讨过氧化物酶体增殖物激活受体γ(PPARγ)激动剂罗格列酮(ROZ)与顺铂联合应用对子宫内膜癌KLE细胞裸鼠移植瘤的生长抑制作用。方法构建子宫内膜癌裸鼠模型。成瘤后,将其随机分成6组:生理盐水对照组(A组),顺铂1mg/kg(B组),顺铂3mg/kg(C组),ROZ50mg/kg(D组),顺铂1mg/kg+ROZ50mg/kg(E组),顺铂3mg/kg+ROZ50mg/kg(F组)。顺铂采取隔天腹腔注射给药,ROZ采取每天灌胃给药。每隔3d测量肿瘤体积,观察药物对肿瘤生长的影响,绘制肿瘤生长曲线。实验第38天处死裸鼠,分离皮下移植瘤并称量其质量计算抑瘤率;免疫组化SP法检测种植瘤组织中核转录因子κB(NF-κB)、人第10号染色体缺失的磷酸酶及张力蛋白同源的基因(PTEN)蛋白的表达。结果 B、C、D、E、F组抑瘤率分别为:24.41%、43.34%、49.67%、78.02%、84.78%,与A组比较差异均具有统计学意义(P<0.05)。E、F组抑制子宫内膜癌的作用强于B、C、D组。免疫组化结果显示PTEN表达增强,NF-κB表达减弱(P<0.05)。结论 ROZ、顺铂可抑制子宫内膜癌移植瘤生长,两者联合应用具有协同作用。
Objective To investigate the inhibitory effect of peroxisome proliferator - activated receptor gamma (PPARγ) agonist rosiglitazone (ROZ) combined with cisplatin on the growth of nude mouse xenografts in nude mice bearing endometrial cancer. Methods To construct a nude mouse model of endometrial cancer. After tumor formation, they were randomly divided into 6 groups: saline control group (group A), cisplatin 1mg / kg (group B), cisplatin 3mg / kg (group C), ROZ50mg / kg 1 mg / kg + ROZ 50 mg / kg (group E), cisplatin 3 mg / kg + ROZ 50 mg / kg (group F). Cisplatin administered intraperitoneally every other day, ROZ daily intragastric administration. Measure the tumor volume every 3 days, observe the effect of the drug on tumor growth, and draw the tumor growth curve. The nude mice were sacrificed on the 38th day of the experiment, the subcutaneously transplanted tumor was isolated and weighed to calculate the tumor inhibition rate. The expression of nuclear factor kappa B (NF-κB), human phosphatase 10 And Tensin homology gene (PTEN) protein expression. Results The tumor inhibition rates in groups B, C, D, E and F were 24.41%, 43.34%, 49.67%, 78.02% and 84.78%, respectively, which were significantly different from those in group A (P <0.05). E, F group inhibited endometrial cancer stronger than the B, C, D group. The results of immunohistochemistry showed that the expression of PTEN increased and the expression of NF-κB decreased (P <0.05). Conclusion ROZ and cisplatin can inhibit the growth of endometrial cancer xenografts, and the synergistic effect of the combination of the two can be obtained.